Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,206 questions in 117 reviews · Common Mental Disorders
current versionsNo studies 387 · 17.5%Ungraded 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Morita therapy vs pharmacological therapy Global state responders · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | RR 1.85 [1.27, 2.69] | 2 studies · 75 participants | Very low |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Measures of anxiety overall mean endpoint score of HAMA (high = poor) · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | 1 study · 103 participants | Very low |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Measures of depression overall mean endpoint score of HAMD (high = poor) · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | 1 study · 56 participants | Very low |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Measures of obsession and compulsion overall mean endpoint score of Y‐BOCS (high = poor) · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | 2 studies · 159 participants | Very low |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Quality of life measures ‐ endpoint data or change data · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Measures of functioning ‐ endpoint data or change data · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy vs pharmacological therapy Acceptability ‐ drop‐outs for any reason · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy vs pharmacological therapy Measures of anxiety overall mean endpoint score of 'Anxiety' and 'Phobic anxiety ' in SCL‐90 (high = poor) · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | 1 study · 39 participants | Very low |
Morita therapy vs pharmacological therapy Measures of depression overall mean endpoint score of 'Depression' in SCL‐90 (high = poor) · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | 1 study · 39 participants | Very low |
Morita therapy vs pharmacological therapy Measures of obsession and compulsion endpoint data or change data · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy vs pharmacological therapy Quality of life measures endpoint data or change data · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy vs pharmacological therapy Measures of functioning endpoint data or change data · people with social phobia Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Global state responders · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | no estimate extracted | NR | No studies |
Morita therapy plus pharmacological therapy vs pharmacological therapy alone Acceptability drop‐outs for any reason · people with anxiety disorders Morita therapy for anxiety disorders in adults (2015) · Cochrane | RR 1.76 [0.47, 6.67] | 2 studies · 172 participants | Very low |
Dance Movement Therapy (DMT) vs standard care or waiting list control Depression score SCL‐90‐R depression sub‐scale (13 items); HAM‐D. Scale from: 0 to 84 (HAM‐D) or 52 (SCL‐90‐R depression sub‐scale). · patients with depression Dance movement therapy for depression (2015) · Cochrane | no estimate extracted | 3 studies · 147 participants | Very low |
Dance Movement Therapy (DMT) vs standard care or waiting list control Drop‐outs drop‐out numbers in each arm · patients with depression Dance movement therapy for depression (2015) · Cochrane | OR 1.82 [0.35, 9.45] | 1 study · 31 participants | Low |
Dance Movement Therapy (DMT) vs standard care or waiting list control Social and occupational functioning SCL‐90‐R. Scale from: 0 to 52. · patients with depression Dance movement therapy for depression (2015) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Dance Movement Therapy (DMT) vs standard care or waiting list control Quality of life MANSA. Scale from: 12 to 84. · patients with depression Dance movement therapy for depression (2015) · Cochrane | no estimate extracted | 1 study · 22 participants | Low |
Dance Movement Therapy (DMT) vs standard care or waiting list control Self esteem Rosenberg. Scale from: 0 to 30. · patients with depression Dance movement therapy for depression (2015) · Cochrane | no estimate extracted | 1 study · 21 participants | Low |
Newer generation antidepressants vs placebo Repetition of SH at last · adults who engage in SH Pharmacological interventions for self‐harm in adults (2015) · Cochrane | OR 0.76 [0.42, 1.36] | 3 studies · 243 participants | Low |
Antipsychotics vs placebo or another comparator drug/dose Repetition of SH at six months (flupenthixol vs. placebo) · adults who engage in SH Pharmacological interventions for self‐harm in adults (2015) · Cochrane | OR 0.09 [0.02, 0.5] | 1 study · 30 participants | Very low |
Antipsychotics vs placebo or another comparator drug/dose Repetition of SH at six months (low dose fluphenazine vs. ultra low dose fluphenazine) · adults who engage in SH Pharmacological interventions for self‐harm in adults (2015) · Cochrane | OR 1.51 [0.5, 4.58] | 1 study · 53 participants | Very low |
Mood stabilisers vs placebo Repetition of SH at 12 months · adults who engage in SH Pharmacological interventions for self‐harm in adults (2015) · Cochrane | OR 0.99 [0.33, 2.95] | 1 study · 167 participants | Low |
Natural products vs placebo Repetition of SH during 12 week treatment phase · adults who engage in SH Pharmacological interventions for self‐harm in adults (2015) · Cochrane | OR 1.33 [0.38, 4.62] | 1 study · 49 participants | Low |
Comparison 1: individual CBT‐based psychotherapy vs treatment Repetition of SH at six months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 1.88 [0.3, 11.73] | 1 study · 39 participants | Very low |
Comparison 8: home‐based family intervention vs treatment Repetition of SH at six months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 1.02 [0.41, 2.51] | 1 study · 149 participants | Low |
Comparison 9: remote contact interventions vs treatment Repetition of SH at 12 months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.5 [0.12, 2.04] | 1 study · 105 participants | Very low |
Comparison 2: interventions for patients with multiple episodes of SH or emerging personality problems vs treatment Repetition of SH at post‐intervention · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.72 [0.12, 4.4] | 2 studies · 105 participants | Low |
Comparison 2: interventions for patients with multiple episodes of SH or emerging personality problems vs treatment Frequency of SH at post‐intervention · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | no estimate extracted | 2 studies · 104 participants | Low |
Comparison 2: interventions for patients with multiple episodes of SH or emerging personality problems vs treatment Mentalisation · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | no estimate extracted | NR | No studies |
Comparison 5: group‐based psychotherapy vs treatment Repetition of SH at six months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 1.72 [0.56, 5.24] | 2 studies · 430 participants | Low |
Comparison 5: group‐based psychotherapy vs treatment Repetition of SH at 12 months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.8 [0.22, 2.97] | 3 studies · 490 participants | Low |
Comparison 6: therapeutic assessment vs treatment Repetition of SH at 12 months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.75 [0.18, 3.06] | 1 study · 69 participants | Low |
Comparison 6: therapeutic assessment vs treatment Repetition of SH at 24 months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.69 [0.23, 2.14] | 1 study · 69 participants | Low |
Comparison 7: compliance enhancement plus treatment as usual (i.e., standard disposition planning) vs treatment Repetition of SH by six months · children and adolescents who engage in SH. Interventions for self‐harm in children and adolescents (2015) · Cochrane | OR 0.67 [0.15, 3.08] | 1 study · 63 participants | Very low |
Intervention NR Response rate at post‐treatment (as defined in individual studies) · women with postnatal depression Antidepressant treatment for postnatal depression (2014) · Cochrane | RR 1.43 [1.01, 2.03] | 3 studies · 146 participants | Very low |
Intervention NR Remission rate at post‐treatment (as defined in individual studies) · women with postnatal depression Antidepressant treatment for postnatal depression (2014) · Cochrane | RR 1.79 [1.08, 2.98] | 3 studies · 146 participants | Very low |
Propranolol vs placebo Treatment efficacy CAPS, CIDI · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the… Pharmacological interventions for preventing post‐traumatic stress disorder (PTSD) (2014) · Cochrane | RR 0.62 [0.24, 1.59] | 3 studies · 118 participants | Low |
Hydrocortisone vs placebo Treatment efficacy CAPS, SCID‐IV, PTSS‐10Q‐I · adult participants (18 years and older) who have been exposed to any traumatic events, but who did not meet the… Pharmacological interventions for preventing post‐traumatic stress disorder (PTSD) (2014) · Cochrane | RR 0.17 [0.05, 0.56] | 4 studies · 165 participants | Moderate |
Paroxetine vs older ADs Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.04 [0.92, 1.17] | 34 studies · 4647 participants | Moderate |
Paroxetine vs agomelatine Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs reboxetine Failure to respond at 1‐4 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.66 [0.5, 0.87] | 3 studies · 1375 participants | Moderate |
Paroxetine vs reboxetine Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs reboxetine Failure to remit at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs reboxetine SMD at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 3 studies · 1291 participants | Moderate |
Paroxetine vs reboxetine Failure to complete ‐ any cause ‐ · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 0.78 [0.51, 1.19] | 3 studies · 1375 participants | Moderate |
Paroxetine vs reboxetine Participants with at least some Side Effects · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.08 [0.74, 1.58] | 3 studies · 1375 participants | Moderate |
Paroxetine vs sertraline Failure to respond at endpoint (6‐12 weeks) · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | OR 1.25 [0.89, 1.77] | 3 studies · 618 participants | Moderate |
Paroxetine vs sertraline Failure to respond at 1‐4 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Paroxetine vs sertraline Failure to respond at 16‐24 weeks · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |